Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The clinical trial page now displays the study record for pembrolizumab-based therapy, including its design, eligibility criteria, locations, and outcome measures, instead of an access-denied error.
    Difference
    59%
    Check dated 2026-11-10T06:53:56.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer now identifies the ClinicalTrials.gov release as v3.8.0 instead of v3.7.2. The page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T03:14:23.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-27T06:30:52.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.
    Difference
    0.2%
    Check dated 2026-10-20T05:49:03.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site revision displayed in the footer changes from v3.7.0 to v3.7.1, while the clinical trial record continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T08:15:00.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the expected study record content. This shows a standard error screen and site footer where study details used to appear.
    Difference
    20%
    Check dated 2026-09-22T03:28:49.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.